Biotech Industry News
A collection of Biotech latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Adaptive Biotechnologies: Q1 Earnings Snapshot
SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Thursday reported a loss of $29.9 million in its first quarter. On a per-share basis, the Seattle-based company said it had a loss of 20 cents. The results…
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial…
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - San Francisco Business Times
The biotech downturn claims another victim, but this deal structure offers a glimmer of hope for Kronos investors.
Biotech Dimerix lands $940m licensing deal for kidney drug sales
ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug. Shares in…
Cyprus Seeds hosts talk on research commercialisation in biotech
Cyprus Seeds and The Cyprus Institute of Neurology & Genetics organized on April 29th 2025, an inspirational speech, “A Scientist Stepping into Entrepreneurship”, by Dr. Mary Lynne Hedley. The event, which took place at the Lefkos…
A Biotech Toolkit for US-China Strategy
Created by the United States Congress in 2022, the National Security Commission on Emerging Biotechnology (NSCEB) is an independent, bipartisan body tasked with assessing biotech's national security implications. Modeled after the earlier AI…
3 Market Predictions For May
After going three for three in March with my market predictions, I went two for three in April. I am doubling down on my one missed prediction in April, as yields should move lower as the jobs picture continues to deteriorate. That and my two other…
Electricity-generating bacteria may power future innovations
A team led by Rice University bioscientist Caroline Ajo-Franklin has discovered how certain bacteria breathe by generating electricity, using a natural process that pushes electrons into their surroundings instead of breathing on oxygen. The…
Amgen beats on both lines and reaffirms guidance; stock flat post market
For the third quarter in a row, Amgen's (NASDAQ:) non-GAAP EPS beat expectations as continued growth in sales of most of its drugs powered the biotech in Q1. Non-GAAP EPS increased 24% year-over-year to $4.90 as product sales overall increased 11%.
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
Market Momentum: Grasping the Dynamic Drivers of Pharmaceutical Growth
The pharmaceutical sector is on overdrive—transforming faster than ever. With a market worth an estimated $1.5 trillion in 2025, the drivers aren't so much traditional demand and supply. They're scientific innovation, digital innovation…
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the…
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS)
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to…
Assessing the impact of Trump's first 100 days on science and health policy
On this week's episode of the Readout LOUD, we review President Trump's first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly's PBM problem. The first 100 days of the Trump administration have had a profound impact on…
Moderna Plans More Cost Cuts on Falling Sales of Covid Shots
Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to offset slowing Covid vaccine sales. The biotech company has been trying to reduce operating expenses as it burns cash on its…
Receive a Daily briefing on Biotech Industry News
Get Started